Patients with autoimmune epilepsy may benefit from early-initiated immunotherapy, shows study published in Archives of Neurology.
"Antiepileptic drugs (AEDs) are the mainstay of treatment for epilepsy, but seizures continue in one-third of patients despite appropriate AED therapeutic trials," the authors write as background in the study. "Even in the current era, the etiology of epilepsy often remains unclear." Additional background information notes that seizures are a common symptom in autoimmune neurologic disorders, such as limbic encephalitis.
To evaluate clinical characteristics and immunotherapy responses in patients with autoimmune epilepsy, Amy M. L. Quek, M.B.B.S., of the Mayo Clinic, College of Medicine, Rochester, Minn., and colleagues, gathered data from the Mayo Clinic computerized diagnostic index from patients who were evaluated in both the Autoimmune Neurology Clinic and Epilepsy Clinic between January 2005 and December 2010, and were diagnosed with autoimmune epilepsy.
The authors identified 32 patients for inclusion in the study. All patients had partial seizures, and 81 percent had failed treatment with two or more AEDs and had daily seizures; the remaining patients had at least one seizure a month. Immunotherapy was started in 27 of 32 patients for treatment of persistent seizures despite AED therapy.
After a median follow-up time of 17 months (range 3-72 months), 22 of 27 patients (81 percent) reported improvement following immunotherapy, and 18 patients were seizure free. Of these 18 patients, eight (44 percent) were seizure free within 12 weeks of immunotherapy initiation. Five patients did not respond to immunotherapy; however, two of the five demonstrated subsequent improvement after AEDs were changed.
"When clinical and serological clues suggest an autoimmune basis for medically intractable epilepsy, early-initiated immunotherapy may improve seizure outcome," the authors conclude. "Clinical experience suggests that immunotherapy should not be used alone to control seizures but should be used in combination with AEDs to optimize seizure control."
Editor's Note: Several of the study authors have listed financial disclosures including funding received from pharmaceutical companies. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.